---

---

tags : Cancer    entities : Astellas pharma inc   

save search

---

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -14.63% | O: 0.82% H: 0.0% C: -2.54%
keytruda license bladder cancer treatment medical application advanced

---

Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -14.31% | O: -1.65% H: 3.36% C: 3.17%
japan approved cancer treatment

---

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -13.49% | O: -0.54% H: 0.0% C: 0.0%
ALPMY | $9.47 520K |

Manufacturing

| -15.63% | O: 2.26% H: 0.0% C: -2.65%
chmp positive cancer treatment

---

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 600K |

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $138.24 800 |

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $63.676 7.2K |

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.47 520K |

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.19 0.23% 740K |

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $94.285 1.85% 1.6M |

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.585 0.8% 1.1M |

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | $727.48 -2.48% 2M |

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.89 1.22% 5.1M |

Health Technology

| -5.13% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $165.97 0.8% 3.1M |

Health Technology

| -6.33% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -3.44% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.41 0.07% 2.9M |

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $267.41 1.77% 1.4M |

Health Technology

| -6.54% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

---

PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-02-15 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -15.48% | O: -2.99% H: 3.82% C: 3.54%
keytruda granted review bladder cancer treatment advanced

---

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $138.24 800 |

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $63.676 7.2K |

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | $9.47 520K |

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | News | $13.19 0.23% 740K |

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | $94.285 1.85% 1.6M |

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -6.93% | O: 1.47% H: 0.0% C: 0.0%
LLY | $727.48 -2.48% 2M |

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.89 1.22% 5.1M |

Health Technology

| -1.95% | O: -0.14% H: 0.35% C: -1.12%
ABBV | News | $165.97 0.8% 3.1M |

Health Technology

| -3.43% | O: 1.48% H: 0.0% C: 0.0%
VRTX | News | $395.0 0.39% 550K |

Health Technology

| -5.09% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -2.19% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | $110.6 1.22% 210K |

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.41 0.07% 2.9M |

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $267.41 1.77% 1.4M |

Health Technology

| -16.18% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

---

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -16.94% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | $9.47 520K |

Manufacturing

| -19.27% | O: 0.0% H: 1.38% C: 0.26%
PFE A | $25.91 2.05% 22M |

Health Technology

| -5.92% | O: 0.56% H: 1.25% C: -0.33%
keytruda drug japan bladder cancer treatment application advanced

---

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -20.51% | O: -6.38% H: 0.88% C: 0.88%
ALPMY | $9.47 520K |

Manufacturing

| -18.36% | O: 0.09% H: 0.17% C: -0.3%
PFE A | $25.91 2.05% 22M |

Health Technology

| -7.46% | O: 0.58% H: 1.01% C: -0.58%
keytruda bladder cancer treatment application advanced

---

Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio
Published: 2024-01-09 (Crawled : 03:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -22.38% | O: 0.16% H: 0.0% C: -3.88%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -11.87% | O: -0.24% H: 0.0% C: 0.0%
ALPMY | $9.47 520K |

Manufacturing

| -23.94% | O: -1.22% H: 0.0% C: -0.72%
NVS | $94.285 1.85% 1.6M |

Health Technology

| -13.07% | O: -0.46% H: 0.74% C: -0.19%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -11.68% | O: 0.74% H: 0.0% C: 0.0%
AMGN | $267.41 1.77% 1.4M |

Health Technology

| -14.78% | O: -0.92% H: 0.63% C: -0.25%
america cancer treatment market

---

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE A | $25.91 2.05% 22M |

Health Technology

| Email alert Add to watchlist
ALPMF | $9.17 16K |

Health Technology

| Email alert Add to watchlist
ALPMY | $9.47 520K |

Manufacturing

| Email alert Add to watchlist
padcev fda first approved bladder cancer treat advanced plus

---

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -18.49% | O: 3.87% H: 0.0% C: 0.0%
ALPMY | $9.47 520K |

Manufacturing

| -23.19% | O: -3.37% H: 4.51% C: 4.51%
PFE A | $25.91 2.05% 22M |

Health Technology

| -16.57% | O: -4.92% H: 1.48% C: -0.21%
padcev fda license review bladder cancer treatment application grants

---

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -17.29% | O: 0.04% H: 0.0% C: 0.0%
ALPMY | $9.47 520K |

Manufacturing

| -19.27% | O: 1.38% H: 1.79% C: 1.79%
PFE A | $25.91 2.05% 22M |

Health Technology

| -14.61% | O: 0.5% H: 0.3% C: 0.0%
xtandi fda approved cancer treatment

---

Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -23.18% | O: -1.46% H: 3.67% C: 3.26%
ZYME | $8.76 1.04% 290K |

Health Technology

| 26.07% | O: 1.14% H: 0.42% C: -0.7%
TAK | News | $13.19 0.23% 740K |

Health Technology

| -3.66% | O: 1.03% H: 0.73% C: 0.58%
ADCT | $4.72 -0.84% 190K |

Health Technology

| 609.28% | O: -0.16% H: 6.42% C: 4.49%
ABBV | News | $165.97 0.8% 3.1M |

Health Technology

| 15.93% | O: -0.86% H: 0.0% C: 0.0%
STRO M | $3.65 -3.18% 230K |

Health Technology

| 47.29% | O: 0.39% H: 3.86% C: 3.86%
IMGN | $31.23 0.03% 49M |

Health Technology

| 109.1% | O: 5.09% H: 5.48% C: -1.27%
GILD | News | $66.45 0.44% 4.3M |

Health Technology

| -16.57% | O: -0.47% H: 1.88% C: 1.78%
EXEL | $22.28 -0.93% 960K |

Health Technology

| 9.54% | O: -2.62% H: 1.17% C: -1.66%
drug antibody breast cancer treatment global market

---

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| Email alert Add to watchlist
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
ALPMY | $9.47 520K |

Manufacturing

| Email alert Add to watchlist
ev-302 padcev bladder cancer trial

---

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published: 2023-09-22 (Crawled : 09:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -34.73% | O: -0.56% H: 1.48% C: 1.12%
SGEN | $228.74 0.1% 20M |

Health Technology

| 10.83% | O: 3.59% H: 0.09% C: -0.05%
ev-302 padcev bladder cancer trial

---

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -37.23% | O: -0.03% H: 1.04% C: -0.37%
PFE A | $25.91 2.05% 22M |

Health Technology

| -25.56% | O: 0.18% H: 1.2% C: -0.38%
xtandi cancer treatment

---

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | $9.47 520K |

Manufacturing

| -38.75% | O: 0.59% H: 0.46% C: 0.46%
PFE A | $25.91 2.05% 22M |

Health Technology

| -31.0% | O: 0.68% H: 0.11% C: -1.16%
xtandi fda review cancer grants

---

Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
Published: 2023-08-07 (Crawled : 21:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -39.35% | O: 0.19% H: 0.0% C: -2.72%
LLY | $727.48 -2.48% 2M |

Health Technology

| 65.34% | O: 11.43% H: 6.32% C: 3.08%
URGN | $13.22 -7.29% 230K |

Health Technology

| -28.35% | O: -1.3% H: 6.76% C: 5.57%
INCY | $52.07 -1.42% 800K |

Health Technology

| -16.99% | O: 2.58% H: 0.41% C: -1.13%
FUSN | $21.24 -0.05% 280K |

Health Technology

| 603.31% | O: 10.6% H: 0.0% C: -9.58%
companies bladder cancer market

---

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
Published: 2023-08-07 (Crawled : 13:00) - prnewswire.com
ALPMF | $9.17 16K |

Health Technology

| -31.96% | O: 9.22% H: 0.0% C: -0.32%
ALPMY | $9.47 520K |

Manufacturing

| -32.9% | O: 11.06% H: 0.0% C: -0.39%
PSTX | News | $1.98 -1.0% 350K |

Health Technology

| 25.46% | O: 32.52% H: 24.54% C: -8.33%
cancer cell therapeutics therapy

---

Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight
Published: 2023-07-05 (Crawled : 21:00) - prnewswire.com
ALPMY | $9.47 520K |

Manufacturing

| -34.65% | O: 0.86% H: 0.0% C: -1.01%
NVS | $94.285 1.85% 1.6M |

Health Technology

| -5.93% | O: -1.17% H: 0.63% C: 0.22%
LLY | $727.48 -2.48% 2M |

Health Technology

| 61.21% | O: -0.55% H: 0.97% C: 0.02%
VERU | $1.375 -3.17% 2.1M |

Health Technology

| 18.33% | O: -0.83% H: 0.0% C: -6.72%
OPK | $1.225 -0.41% 1.1M |

Health Technology

| -41.43% | O: -1.19% H: 1.2% C: -0.72%
ADXS | $0.57 9.5K |

Health Technology

| -40.0% | O: 0.0% H: 0.0% C: -6.83%
cancer global growth market

---

Gainers vs Losers

71%

29%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M |

Finance

EGOX | $0.0503 39.72% 320M |

RWOD | $10.52 31.56% 5.9M |

n/a

ZCMD | $1.905 31.38% 30M |

Commercial Services

MRDB 4 | $0.536 27.65% 2M |

n/a

BSFC | $0.0822 27.64% 75M |

Manufacturing

TPET | $0.4121 25.68% 45M |

n/a

NVFY | $2.65 25.59% 33M |

Consumer Durables

INDO | $5.1 25.0% 15M |

Energy Minerals

CHRO | $1.53 24.9% 100K |

n/a

---

Your saved searches

---